Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Sep;20(3):291–297. doi: 10.1128/aac.20.3.291

Acyclovir treatment of experimental simian varicella infection of monkeys.

K F Soike, A D Felsenfeld, P J Gerone
PMCID: PMC181690  PMID: 7305319

Abstract

Replication of simian varicella virus (SVV) in Vero cell cultures was inhibited by acyclovir, 9-(2-hydroxyethoxymethyl)guanine (ACV), at a concentration of 10 micrograms/ml in culture medium. Intravenous administration of ACV at 10 mg/kg twice a day for 10 days or 15 mg/kg three times a day for 5 days to patas monkeys (Erythrocebus patas) beginning 48 h after SVV inoculation blocked the appearance of rash and other clinical symptoms but did not affect viremia. ACV treatment of African green monkeys (Cercopithecus aethiops) at 10 mg/kg twice a day by intravenous injection beginning 24 or 72 h after SVV inoculation and continuing for 10 days had no effect on clinical symptoms, including the development of rash, or on the appearance of viremia. The minimal therapeutic results could be due to the observation that doses of 10 or 15 mg/kg produced plasma levels of ACV which were lower than 5 micrograms/ml, the concentration that inhibited SVV multiplication in vitro, and decayed rapidly.

Full text

PDF
291

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biron K. K., Elion G. B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447. doi: 10.1128/aac.18.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cheng Y. C., Tsou T. Y., Hackstadt T., Mallavia L. P. Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and kinetic properties of the virus-induced thymidine kinase. J Virol. 1979 Jul;31(1):172–177. doi: 10.1128/jvi.31.1.172-177.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coen D. M., Schaffer P. A. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2265–2269. doi: 10.1073/pnas.77.4.2265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Crumpacker C. S., Schnipper L. E., Zaia J. A., Levin M. J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother. 1979 May;15(5):642–645. doi: 10.1128/aac.15.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  6. Dobersen M. J., Jerkofsky M., Greer S. Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine. J Virol. 1976 Nov;20(2):478–486. doi: 10.1128/jvi.20.2.478-486.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Felsenfeld A. D., Abee C. R., Gerone P. J., Soike K. F., Williams S. R. Phosphonoacetic acid in the treatment of simian varicella. Antimicrob Agents Chemother. 1978 Sep;14(3):331–335. doi: 10.1128/aac.14.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Felsenfeld A. D., Schmidt N. J. Antigenic relationships among several simian varicella-like viruses and varicella-zoster virus. Infect Immun. 1977 Mar;15(3):807–812. doi: 10.1128/iai.15.3.807-812.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Field H. J., Bell S. E., Elion G. B., Nash A. A., Wildy P. Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother. 1979 Apr;15(4):554–561. doi: 10.1128/aac.15.4.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jones B. R., Coster D. J., Fison P. N., Thompson G. M., Cobo L. M., Falcon M. G. Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers. Lancet. 1979 Feb 3;1(8110):243–244. doi: 10.1016/s0140-6736(79)90769-4. [DOI] [PubMed] [Google Scholar]
  11. Kaufman H. E., Varnell E. D., Centifanto Y. M., Rheinstrom S. D. Effect of 9-(2-hydroxyethoxymethyl)guanine on herpesvirus-induced keratitis and iritis in rabbits. Antimicrob Agents Chemother. 1978 Dec;14(6):842–845. doi: 10.1128/aac.14.6.842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klein R. J., Friedman-Kien A. E., DeStefano E. Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother. 1979 May;15(5):723–729. doi: 10.1128/aac.15.5.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mayo D. R., Richards J. C., Rapp F. Acycloguanosine treatment of herpesvirus infections in footpads and nervous tissue of normal and immunosuppressed mice. Intervirology. 1980;12(6):345–348. doi: 10.1159/000149095. [DOI] [PubMed] [Google Scholar]
  14. Park N. H., Pavan-Langston D., Hettinger M. E., McLean S. L., Albert D. M., Lin T. S., Prusoff W. H. Topical therapeutic efficacy of 9-(2-hydroxyethoxymethyl)guanine and 5-iodo-5'-amino-2',5'-dideoxyuridine on oral infection with herpes simplex virus in mice. J Infect Dis. 1980 May;141(5):575–579. doi: 10.1093/infdis/141.5.575. [DOI] [PubMed] [Google Scholar]
  15. Park N. H., Pavan-Langston D., McLean S. L. Acylovir in oral and ganglionic herpes simplex virus infections. J Infect Dis. 1979 Nov;140(5):802–806. doi: 10.1093/infdis/140.5.802. [DOI] [PubMed] [Google Scholar]
  16. Park N. H., Pavan-Langston D., McLean S. L., Albert D. M. Therapy of experimental herpes simplex encephalitis with aciclovir in mice. Antimicrob Agents Chemother. 1979 Jun;15(6):775–779. doi: 10.1128/aac.15.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
  18. Schnipper L. E., Crumpacker C. S. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2270–2273. doi: 10.1073/pnas.77.4.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Selby P. J., Powles R. L., Janeson B., Kay H. E., Watson J. G., Thornton R., Morgenstern G., Clink H. M., McElwain T. J., Prentice H. G. Parenteral acyclovir therapy for herpesvirus infections in man. Lancet. 1979 Dec 15;2(8155):1267–1270. doi: 10.1016/s0140-6736(79)92281-5. [DOI] [PubMed] [Google Scholar]
  20. Smith K. O., Kennell W. L., Poirier R. H., Lynd F. T. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine). Antimicrob Agents Chemother. 1980 Feb;17(2):144–150. doi: 10.1128/aac.17.2.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Soike K. F., Felsenfeld A. D., Gibson S., Gerone P. J. Ineffectiveness of adenine arabinoside and adenine arabinoside 5'-monophosphate in simian varicella infection. Antimicrob Agents Chemother. 1980 Jul;18(1):142–147. doi: 10.1128/aac.18.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. de Miranda P., Whitley R. J., Blum M. R., Keeney R. E., Barton N., Cocchetto D. M., Good S., Hemstreet G. P., 3rd, Kirk L. E., Page D. A. Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther. 1979 Dec;26(6):718–728. doi: 10.1002/cpt1979266718. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES